BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA ClearanceZacks Investment Research • 03/28/25
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug AdministrationGlobeNewsWire • 03/27/25
Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene TherapySeeking Alpha • 03/21/25
BEAM Down Despite Positive Initial Data From Genetic Disorder StudyZacks Investment Research • 03/11/25
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via EquityBenzinga • 03/10/25
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing MutationGlobeNewsWire • 03/10/25
Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/25/25
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated CatalystsGlobeNewsWire • 02/25/25
Wall Street Analysts See a 67.27% Upside in Beam Therapeutics (BEAM): Can the Stock Really Move This High?Zacks Investment Research • 02/13/25
Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 02/10/25
Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 84.45%: Read This Before Placing a BetZacks Investment Research • 01/28/25
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTRGlobeNewsWire • 01/23/25
Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated CatalystsGlobeNewsWire • 01/13/25
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/08/24
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/07/24